SPORE in Prostate Cancer

这是西北大学Robert H. Lurie综合癌症中心和芝加哥大学癌症研究中心的前列腺癌SPORE更新修订申请。总的来说，审稿人指出，该项目在研究人员的专业知识、庞大的患者群体和高度支持孢子的环境方面具有相当大的优势。我们对审查委员会提出的意见进行了广泛的修订，从而进一步加强了整个计划。主要的变化可以在项目4中找到，我们现在专注于动物研究和临床试验，而在项目2中，我们取消了进行动物研究的一个目标。修订后的申请包含四个高度转化的研究项目：(1)5a-还原酶抑制前列腺癌的间断雄激素消融治疗（Wang & Shevrin）， (2) PEDF调节前列腺癌中的脂肪生成和瘦素（Crawford， Gapstur和Lee），(3)放射诱导的前列腺癌tnf - α治疗（Weichselbaum & Stadler）和(4)化学预防剂染料木素（Bergan & Catalona）调节前列腺癌细胞运动。这些项目代表了前列腺癌转化研究的平衡方法，包括预防（项目4）、分子流行病学（项目2）、雄激素敏感晚期癌症的管理（项目1）和局部疾病的治疗（项目3）。SPORE的领导强调了拟议的四个核心的高度互动结构，包括行政核心，标本采购核心，生物统计学/生物信息学核心以及临床试验和倡导核心。SPORE也有灵活的、结构化的发展研究和职业发展计划，以鼓励更多的研究人员在前列腺癌研究中采取主动行动，并迅速响应新的研究机会。内部和外部咨询委员会评估项目进展，并为SPORE首席研究员和联合首席研究员提供指导。我们觉得修改后的申请有了很大的改进，我们非常感谢审稿人提供的有用意见。

This is a revised application for renewal of the SPORE in Prostate Cancer at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and the Cancer Research Center of the University of Chicago. Overall, the reviewers noted that the Program had considerable merit with strengths in the expertise of the investigators, large patient population and an environment highly supportive of the SPORE. We have responded to the comments made by the review committee through extensive revisions and, thus, have further enhanced the program throughout. The major changes can be found in Project 4 where we now focus on animal studies and a clinical trial and in Project 2 where we have eliminated one aim to conduct animal studies. The revised application contains four highly translational research projects: (1) 5a-Reductase Inhibition in Intermittent Androgen Ablation Therapy of Prostate Cancer (Wang & Shevrin), (2) PEDF Regulation of Adipogenesis and Leptin in Prostate Cancer (Crawford, Gapstur and Lee), (3) Radiation-lnducible TNF-alpha Therapy in Prostate Cancer (Weichselbaum & Stadler) and (4) Modulation of Prostate Cancer Cell Motility by the Chemopreventive Agent Genistein (Bergan & Catalona). These projects represent a balanced approach in prostate cancer translational research, including prevention (Project 4), molecular epidemiology (Project 2), management of androgen-sensitive advanced cancer (Project 1), and therapy of local disease (project 3). The leadership of the SPORE emphasizes the highly interactive structures in place for the proposed four cores, that include the Administrative Core, the Specimen Procurement Core, the Biostatistics/Bioinformatics Core, and the Clinical Trials and Advocacy Core. The SPORE also has flexible, yet structured, Developmental Research and Career Development Programs to encourage additional investigators to undertake initiatives in prostate cancer research and to quickly respond to new research opportunities. The Internal and External Advisory Committees evaluate program progress and offer guidance to the SPORE principal investigator and co-principal investigators. We feel that the revised application is significantly improved, and we are grateful to the reviewers for their helpful comments.